A review by Zheng et al. at the University of Texas at San Antonio synthesizes evidence that antimicrobial peptides (AMPs) and disease-related amyloid peptides can cross-seed and modulate each other's aggregation.
A New Link Between Infection and Neurodegeneration
Antimicrobial peptides (AMPs) and amyloid-forming peptides have traditionally been studied in separate scientific domains—AMPs as frontline immune defenders, and amyloids as the pathological aggregates behind diseases like Alzheimer's and Parkinson's. However, a new review reveals that these two families share far more than previously thought.
Both groups exhibit β-sheet-rich conformations, fibrillar self-assembly, and membrane-disruption mechanisms. This structural and functional overlap suggests a deep, bidirectional relationship that may link infection biology directly to chronic neurodegeneration.
Three Key Mechanisms of Interaction
The authors identify three core mechanisms through which AMPs and amyloids influence each other:
- Structural Compatibility: Shared β-sheet topologies allow AMPs and amyloids to physically interact and "cross-seed" each other's aggregation.
- Directional Seeding Asymmetry: One peptide type can seed the aggregation of the other, but this effect is not always reciprocal, creating complex patterns of influence.
- Surface-Mediated Catalysis: Cell membranes act as catalytic surfaces, accelerating the cross-seeding interactions between these peptides.
The review proposes a self-reinforcing feedback loop: microbial infection stimulates AMP and amyloid production, while amyloid aggregates amplify neuroinflammation.
This framework provides a unified mechanistic model for how a simple infection could trigger or accelerate the processes underlying chronic neurodegenerative diseases.
Designing Dual-Function Therapeutics
Looking toward therapeutic applications, the review discusses the rational design of dual-function peptides—molecules engineered to simultaneously inhibit amyloid aggregation while retaining their antimicrobial activity. This represents a promising new strategy for addressing the intertwined pathologies of infection and neurodegeneration.
Remaining Challenges
Despite the conceptual advance, significant open challenges remain. Determining the specific sequence features that govern selective amyloid recognition is a critical next step. Without this knowledge, designing precise therapeutic agents is difficult.
Furthermore, any potential peptide-based therapy must overcome major hurdles in improving in vivo stability and delivery—two longstanding obstacles in the field of peptide therapeutics.
The findings highlight a potential link between infection biology and neurodegeneration, proposing that cross-seeding interactions between AMPs and amyloids may contribute to chronic disease progression.